120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
TRIM14-KIF1B 轴通过调节 TLR4/NF-κB 通路驱动糖尿病肾病肾损伤
Authors Chen J, Han X, Cao Y , Song J, Wang C, Pan T
Received 1 September 2025
Accepted for publication 31 January 2026
Published 10 February 2026 Volume 2026:19 562762
DOI https://doi.org/10.2147/DMSO.S562762
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Rebecca Baqiyyah Conway
Jianfeng Chen,1,2 Xiaofang Han,2 Yonghong Cao,2 Jiajia Song,2 Chen Wang,3 Tianrong Pan1
1Department of Endocrinology, The Second Affiliated Hospital of Anhui Medical University, Anhui, People’s Republic of China; 2Department of Endocrinology, The Second People’s Hospital of Hefei (Hefei Hospital Affiliated to Anhui Medical University), Anhui, People’s Republic of China; 3Department of Pharmaceutical Science and Engineering, School of Food and Biological Engineering, Hefei University of Technology, Anhui, People’s Republic of China
Correspondence: Tianrong Pan, Department of Endocrinology, The Second Affiliated Hospital of Anhui Medical University, No. 678 of Furong Road, Jingkai District, Hefei, Anhui, 230601, People’s Republic of China, Email ptr1968@163.com
Background: Diabetic nephropathy (DN), a major contributor to end-stage renal disease, remains poorly understood at the molecular level. While the roles of TRIM proteins in metabolic diseases are emerging, the specific function of Tripartite Motif Containing 14 (TRIM14) in DN and its novel interaction with Kinesin Family Member 1B (KIF1B) have not been explored. This study aims to investigate this uncharted mechanistic axis.
Methods: A rat DN model was established using a high-fat diet and streptozotocin injection. Transcriptome sequencing, functional enrichment, and protein-protein interaction (PPI) network analyses were performed to identify key regulatory genes and novel interactions. In vitro, high-glucose-exposed HK-2 cells were used for functional assays. The interaction between TRIM14 and KIF1B was validated by co-immunoprecipitation (Co-IP) and immunofluorescence. TRIM14 expression was also assessed in DN patient blood samples via qPCR.
Results: Transcriptomic profiling revealed significant enrichment of immune and metabolic pathways in DN, with TRIM14 emerging as a central regulatory gene. TRIM14 expression was markedly elevated in DN rat kidneys (approximately 2-fold increase, p < 0.001), high-glucose-stimulated HK-2 cells (2-fold increase, p < 0.01), and DN patient blood. Knockdown of TRIM14 significantly mitigated high-glucose-induced apoptosis, oxidative stress, and inflammation in HK-2 cells, partially by suppressing the TLR4/NF-κB pathway. Crucially, PPI analysis and Co-IP confirmed KIF1B as a novel and direct TRIM14 interactor, with TRIM14 positively regulating KIF1B expression and co-localizing in HK-2 cells.
Conclusion: We report for the first time that the TRIM14-KIF1B axis acts as a key driver of renal injury in DN. TRIM14 exacerbates tubular epithelial cell damage via KIF1B modulation and TLR4/NF-κB activation. TRIM14 represents a promising diagnostic biomarker and therapeutic target for DN.
Keywords: diabetic nephropathy, TRIM14, KIF1B, TLR4/NF-κB pathway, apoptosis
1Department of Endocrinology, The Second Affiliated Hospital of Anhui Medical University, Anhui, People’s Republic of China; 2Department of Endocrinology, The Second People’s Hospital of Hefei (Hefei Hospital Affiliated to Anhui Medical University), Anhui, People’s Republic of China; 3Department of Pharmaceutical Science and Engineering, School of Food and Biological Engineering, Hefei University of Technology, Anhui, People’s Republic of China
Correspondence: Tianrong Pan, Department of Endocrinology, The Second Affiliated Hospital of Anhui Medical University, No. 678 of Furong Road, Jingkai District, Hefei, Anhui, 230601, People’s Republic of China, Email ptr1968@163.com
Background: Diabetic nephropathy (DN), a major contributor to end-stage renal disease, remains poorly understood at the molecular level. While the roles of TRIM proteins in metabolic diseases are emerging, the specific function of Tripartite Motif Containing 14 (TRIM14) in DN and its novel interaction with Kinesin Family Member 1B (KIF1B) have not been explored. This study aims to investigate this uncharted mechanistic axis.
Methods: A rat DN model was established using a high-fat diet and streptozotocin injection. Transcriptome sequencing, functional enrichment, and protein-protein interaction (PPI) network analyses were performed to identify key regulatory genes and novel interactions. In vitro, high-glucose-exposed HK-2 cells were used for functional assays. The interaction between TRIM14 and KIF1B was validated by co-immunoprecipitation (Co-IP) and immunofluorescence. TRIM14 expression was also assessed in DN patient blood samples via qPCR.
Results: Transcriptomic profiling revealed significant enrichment of immune and metabolic pathways in DN, with TRIM14 emerging as a central regulatory gene. TRIM14 expression was markedly elevated in DN rat kidneys (approximately 2-fold increase, p < 0.001), high-glucose-stimulated HK-2 cells (2-fold increase, p < 0.01), and DN patient blood. Knockdown of TRIM14 significantly mitigated high-glucose-induced apoptosis, oxidative stress, and inflammation in HK-2 cells, partially by suppressing the TLR4/NF-κB pathway. Crucially, PPI analysis and Co-IP confirmed KIF1B as a novel and direct TRIM14 interactor, with TRIM14 positively regulating KIF1B expression and co-localizing in HK-2 cells.
Conclusion: We report for the first time that the TRIM14-KIF1B axis acts as a key driver of renal injury in DN. TRIM14 exacerbates tubular epithelial cell damage via KIF1B modulation and TLR4/NF-κB activation. TRIM14 represents a promising diagnostic biomarker and therapeutic target for DN.
Keywords: diabetic nephropathy, TRIM14, KIF1B, TLR4/NF-κB pathway, apoptosis